F2G
F2G is a clinical-stage biopharmaceutical company developing orotomides, a novel class of antifungal agents. Its lead candidate, Olorofim, targets rare and resistant mold infections and has received multiple regulatory designations.
F2G is a clinical-stage biopharmaceutical company developing orotomides, a novel class of antifungal agents. Its lead candidate, Olorofim, targets rare and resistant mold infections and has received multiple regulatory designations.
